 |
|
Pneumococcal conjugate vaccines: choice of schedule and product development
Jin Lee
Clin Exp Pediatr. 2020;63(7):259-260. Published online 2020 Apr 27 DOI: https://doi.org/10.3345/cep.2019.01739
|
|
Citations to this article as recorded by
 Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review
Vijay Yewale, Pallab Chatterjee, Sanjay M. Marathe, Santosh Taur, Sripriya Sathyanarayanan
Human Vaccines & Immunotherapeutics.2025;[Epub] CrossRef Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule
Shahrul Mt-Isa, Justin R. Chumbley, Matthew S. Kelly, Jessica Weaver, Natalie Banniettis
Expert Review of Vaccines.2025; 24(1): 946. CrossRef Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
Josiah Ryman, Jeffrey R. Sachs, Natalie Banniettis, Thomas Weiss, Maurice Ahsman, Ka Lai Yee, Jessica Weaver
Expert Review of Vaccines.2024; 23(1): 467. CrossRef
|